|
Published by: Business Monitor International
Published: Feb. 26, 2008 - 72 Pages
Table of Contents
- Executive Summary
- Netherlands Pharmaceuticals And Healthcare Industry S
- Pharmaceutical Business Environment Ratings
- Pharmaceutical Ratings - Revised Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- The Netherlands Business Enviroment Ratings
- Table: Western European Pharmaceutical Business Environment Ratings
- Limits To Potential Returns
- Risks To Realisation Of Returns
- Western Europe Overview
- The Netherlands - Market Summary
- Regulatory Regime
- Intellectual Property Developments
- Pricing And Reimbursement
- OTC Medicines
- Industry Developments
- Healthcare Sector
- Healthcare Insurance
- Table: Key Points - Dutch Health Insurance Act, January 1 2006
- Health Profile
- Pharmaceuticals Sector
- Recent Domestic Companies’ Activities
- Recent Foreign Companies’ Activities
- Research And Development Sector
- Industry Forecast Sce34
- Overall Market Forecast
- Table: The Netherlands Drug Market Forecast Indicators
- Key Growth Factors - Industry
- Table: Netherlands Health Expenditure Indicators
- Key Growth Factors - Macroeconomic
- Table: Netherlands - Macroeconomic Forecasts
- Prescription Market Forecast
- Table: The Netherlands’ Prescription Drug Market Forecast Indicators (US$mn unless otherwise stated)
- Over-The-Counter Market Forecast
- Table: The Netherlands OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
- Generics And Branded Market Forecasts
- Table: The Netherlands’ Generics And Branded Market Forecast Indicators
- Export/Import Forecasts
- Table: The Netherlands’ Pharmaceutical Trade Forecast Indicators (US$mn)
- Key Risks To BMI’s Forecast Scenario
- Competitive Landscape
- Netherlands Pharmaceuticals & Healthcare Report Q1 2008
- Company Profiles
- Leading Multinational Manufacturers
- Merck & Co
- Pfizer
- GlaxoSmithKline (GSK)
- Sanofi-Aventis
- Novartis
- Indigenous Manufacturers
- Akzo Nobel
- DSM
- Qiagen
- Pharming Group
- Crucell
- BMI Forecast Modelling
- How We Generate Our Industry Forecasts
- Pharmaceutical Industry
- Sources
AbstractThe drug market in the Netherlands is continuing to develop, aided by favourable economic conditionsand a modern health sector, often cited as one of the most effective systems in the world. Over theforecast period we expect sales to expand at a compound annual growth rate (CAGR) of 2.46%, which ismodest compared with the more dynamic markets further east, but is in line with the mature WesternEuropean market. The main drivers will be the generics sector, which is benefiting from increasinggovernment support. However low consumption patterns, in direct opposite to nearby France, arecontinuing to have a deflationary impact on the overall sector.
The Netherlands’ healthy economy and stable political environment are key assets and should help tounderpin the drug market. According to BMI’s Country Risk team GDP should grow by 3% in 2007,ahead of most of the Eurozone economies. Meanwhile the gradual liberalisation of the over-the counter(OTC) should help the pharmaceutical sector to develop. In July 2007, the government mandated the saleof some OTC products in supermarkets and hypermarkets without the presence of a pharmacist. Althoughonly low-dosage products, considered to have minimal risk, will be available, it should still presentconsiderable upside to sector growth. BMI forecasts that OTC drugs will reach a value of US$0.89bn by2012.
BMI, however, has downgraded growth forecasts for the generics drug sector following planned pricecuts. A two-year multiparty agreement will force a 10% reduction in the prices for off-patent brandeddrugs and their generic equivalents. Meanwhile, drugs with patents set to expire in 2008 will face a 50%price cut. Even though a fall in price often causes a spike in volume sales, BMI still believes the measureswill have a negative impact.
Meanwhile, the Netherlands takes sixth position in BMI’s Business Environment Rankings for theWestern European Region. We have completely overhauled the methodology in Q108 giving greaterweight to regulatory factors affecting the drug market, while utilising a more nuanced analysis of countryspecificeconomic and political factors. The Netherlands’ position derives mainly from stagnant growth inits drug market and low per-capita spending.
Get Full Details About This Report >>
|
